Replimune Group announced that the FDA issued a complete response letter rejecting its Biologics License Application for RP1 combined with nivolumab to treat advanced melanoma. The company and FDA disagreed on the adequacy of the submitted data, causing Replimune's shares to drop 64.3% on April 13, 2026. The Schall Law Firm is investigating potential securities law violations and inviting affected investors to join a fraud lawsuit. This development raises concerns about the company's drug approval prospects and investor losses.
AlphaPepe's presale is nearing sell-out at Stage 16, having raised over $1.25 million and attracted more than 8,700 holders. The project also boasts over 4,000 active users on its AlphaSwap AI-powered decentralized exchange demo and has completed a 1...
Nvidia continues to be a core holding due to solid revenue and earnings quality, but further stock accumulation is paused ahead of its upcoming earnings report. While hyperscaler capital expenditure, a key revenue driver, shows ongoing growth, recent...
NextEra Energy is in talks to acquire Dominion Energy in a deal valued at about $66 billion, offering roughly $76 per share, a 21% premium. The transaction would be mostly stock-based, with NextEra shareholders owning about 75% of the combined compan...
Japan's top online brokerages, SBI Securities and Rakuten Securities, are launching Bitcoin and Ethereum investment trusts accessible through regular brokerage accounts. This move simplifies crypto investing by eliminating the need for separate crypt...
Bitcoin long-term holders have increased their holdings to 15.26 million BTC, the highest since August 2025, showing renewed investor confidence despite economic uncertainty. Over the past month, nearly 316,000 BTC were added by these holders, revers...
